Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need

Blood (2025) 146 (Supplement 1): 2756.

https://doi.org/10.1182/blood-2025-2756

Published: 2025

Journal Articles

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

Blood (2025) 146 (Supplement 1): 5341.

https://doi.org/10.1182/blood-2025-5341

Published: 2025

Journal Articles

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

William Johnson, Joseph Rocco, Rikita Patel, Adrianna Herskovits, Elena Mead, Jae Park, Alison Moskowitz, Zachary Epstein-Peterson, Robert Stuver, Neil Bapodra, Rabeya Molla, Andrew Intlekofer, Jennifer Lue, Lia Palomba, Ariela Noy, Jasmine Zain, Colette Owens, Lynnette Henshaw, Paola Ghione, Efrat Luttwak, Pallawi Torka, Andrew Zelenetz, Philip Caron, Anita Kumar, Lorenzo Falchi, Natasha Galasso, Paul Hamlin, Alexander Boardman, Kevin David, Raphael Steiner, Nivetha Ganesan, Tiffany Chang, Zainab Shahid, Wenbin Xiao, Annamaria Ballweg, Alina Markova, Mark Geyer, Lauren Banaszak, Roni Shouval, Sergio Giralt, Gregory Goldgof, Jodi Mones, Jeffrey Zwicker, Rekha Parameswaran, Avi Leader, Cy R. Wilkins, Simon Mantha, Jeffrey Cohen, Jessica Durkee-Shock, Matthew Sedlock, Bita Shakoory, Irini Sereti, Miguel-Angel Perales, Gilles Salles, Santosha Vardhana, Joseph Oved, Steven Horwitz

Blood (2025) 146 (Supplement 1): 2996.

https://doi.org/10.1182/blood-2025-2996

Published: 2025

Journal Articles

Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial

Blood (2025) 146 (Supplement 1): 1850.

https://doi.org/10.1182/blood-2025-1850

Published: 2025

Journal Articles

MSK-impact heme accurately reproduces diffuse large B-cell (DLBCL) dlbclass cluster classification across clinical scenarios, including diagnosis, relapse, and histological transformation

Blood (2025) 146 (Supplement 1): 1766.

https://doi.org/10.1182/blood-2025-1766

Published: 2025

Journal Articles

The surpass trial: a phase 2/3 registrational trial of ELA026 in subjects with treatment-Naïve secondary hemophagocytic lymphohistiocytosis

Swami Iyer, Abhishek Maiti, Prakash Satwani, Kelly Covert, Allison Naumovski, Brian Mangal, Graham Parry, Kathy Dong, Kim-Hien Dao, William Johnson

Blood (2025) 146 (Supplement 1): 1223.

https://doi.org/10.1182/blood-2025-1223

Published: 2025

Journal Articles

Insights in the management of older adults with mantle cell lymphoma amidst a changing therapeutic landscape: Lessons from a 25-year institutional experience

Blood (2025) 146 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2025-1811

Published: 2025

Journal Articles

Outcomes of second-line systemic therapy for relapsed or refractory peripheral T-cell lymphomas: A single-center, retrospective analysis

Zachary Epstein-Peterson, Nivetha Ganesan, Ellie Casper, Tiffany Chang, Ahmet Dogan, Ozgur Can Eren, Natasha Galasso, Paola Ghione, Kelly Hannigan, Varun Iyengar, William Johnson, Jason Krastein, Katie Ksanznak, Alison Moskowitz, Brittney Munayiri, Benedetta Sordi, Robert Stuver, Jasmine Zain, Steven Horwitz

Blood (2025) 146 (Supplement 1): 5412.

https://doi.org/10.1182/blood-2025-5412

Published: 2025

Journal Articles

Integrated dissociated and spatial single-cell profiling reveals that HDAC inhibition restores anti-PD-1 sensitivity in Hodgkin lymphoma by disrupting monocyte-Hodgkin-reed-sternberg cell-driven immunosuppressive niches.

Blood (2025) 146 (Supplement 1): 150.

https://doi.org/10.1182/blood-2025-150

Published: 2025

Journal Articles

Transformed Waldenström macroglobulinemia is associated with poor outcomes and chemorefractory disease

Blood (2025) 146 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2025-3573

Published: 2025

Journal Articles

Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis

Blood (2025) 146 (Supplement 1): 3641.

https://doi.org/10.1182/blood-2025-3641

Published: 2025

Journal Articles

Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study

Blood (2025) 146 (Supplement 1): 3605.

https://doi.org/10.1182/blood-2025-3605

Published: 2025

Journal Articles

Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial

Blood (2025) 146 (Supplement 1): 1971.

https://doi.org/10.1182/blood-2025-1971

Published: 2025

Journal Articles

Are all GELF criteria created equal? utility of individual GELF criteria as guidance for treatment initiation in patients with advanced stage FL

Blood (2025) 146 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2025-1008

Published: 2025

Journal Articles

Cumulative Incidence of Myeloid Neoplasms in Patients with Nodal T-Follicular Helper Cell Lymphoma

Robert Stuver, Nivetha Ganesan, Ahmet Dogan, Zachary D. Epstein-Peterson, Paola Ghione, William Johnson, Natasha Lewis, Alison Moskowitz, Gunjan L. Shah, Michael Scordo, Wenbin Xiao, Steven M. Horwitz

Blood (2023) 142 (Supplement 1): 4438.

https://doi.org/10.1182/blood-2023-182272

Published: 2023

Journal Articles

Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma -Real World Experience

Blood (2023) 142 (Supplement 1): 3059.

https://doi.org/10.1182/blood-2023-189617

Published: 2023

Journal Articles

Infectious Complications in Patients with Relapsed or Refractory (R/R) Non-Hodgkin's Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (BsAb) Mosunetuzumab

Blood (2023) 142 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2023-187911

Published: 2023

Journal Articles

Cutaneous T-Cell Lymphoma and Dupilumab Use: A Retrospective Matched Cohort Study of Clinical Characteristics and Treatment Outcomes

Robert Stuver, Stephen Dusza, Zachary D. Epstein-Peterson, Paola Ghione, William Johnson, Alison Moskowitz, Patricia Myskowski, Melissa Pulitzer, Steven M. Horwitz, Shamir Geller

Blood (2023) 142 (Supplement 1): 6184.

https://doi.org/10.1182/blood-2023-182223

Published: 2023

Journal Articles

Distinct Patterns of CD4+ and CD8+ T-Cell Clonal Expansion Enable Broad Clinical Responses to Pembrolizumab + GVD in Patients with Relapsed Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 1623.

https://doi.org/10.1182/blood-2023-185083

Published: 2023

Journal Articles

Impact of Early Histological Transformation on Survival in Patients with Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 3023.

https://doi.org/10.1182/blood-2023-190325

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial

MSK-impact heme accurately reproduces diffuse large B-cell (DLBCL) dlbclass cluster classification across clinical scenarios, including diagnosis, relapse, and histological transformation

The surpass trial: a phase 2/3 registrational trial of ELA026 in subjects with treatment-Naïve secondary hemophagocytic lymphohistiocytosis

Insights in the management of older adults with mantle cell lymphoma amidst a changing therapeutic landscape: Lessons from a 25-year institutional experience

Outcomes of second-line systemic therapy for relapsed or refractory peripheral T-cell lymphomas: A single-center, retrospective analysis

Integrated dissociated and spatial single-cell profiling reveals that HDAC inhibition restores anti-PD-1 sensitivity in Hodgkin lymphoma by disrupting monocyte-Hodgkin-reed-sternberg cell-driven immunosuppressive niches.

Transformed Waldenström macroglobulinemia is associated with poor outcomes and chemorefractory disease

Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis

Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study

Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial

Are all GELF criteria created equal? utility of individual GELF criteria as guidance for treatment initiation in patients with advanced stage FL

Cumulative Incidence of Myeloid Neoplasms in Patients with Nodal T-Follicular Helper Cell Lymphoma

Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma -Real World Experience

Infectious Complications in Patients with Relapsed or Refractory (R/R) Non-Hodgkin's Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (BsAb) Mosunetuzumab

Cutaneous T-Cell Lymphoma and Dupilumab Use: A Retrospective Matched Cohort Study of Clinical Characteristics and Treatment Outcomes

Distinct Patterns of CD4+ and CD8+ T-Cell Clonal Expansion Enable Broad Clinical Responses to Pembrolizumab + GVD in Patients with Relapsed Hodgkin Lymphoma

Impact of Early Histological Transformation on Survival in Patients with Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only